In English | En español
Questions About Cancer? 1-800-4-CANCER
  • Posted: 05/07/2012

Find News Releases

Search For:
Between these dates:

Page Options

  • Print This Page
  • Email This Document
NCI Cancer Center News

Pitt study finds genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer

While active monitoring of serum prostate specific antigen (PSA) levels in men over 50 has greatly improved early detection of prostate cancer, prediction of clinical outcomes after diagnosis remains a major challenge. Researchers from the University of Pittsburgh School of Medicine have found that a genetic abnormality known as copy number variation (CNV) in prostate cancer tumors, as well as in the benign prostate tissues adjacent to the tumor and in the blood of patients with prostate cancer, can predict whether a patient will experience a relapse, and the nature of the relapse — aggressive or indolent. Their report is published in the June issue of The American Journal of Pathology.

Click here to read full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

This text may be reproduced or reused freely. Please credit the National Cancer Institute as the source. Any graphics may be owned by the artist or publisher who created them, and permission may be needed for their reuse.